EDRIA
BIOR

Edmonds Duncan Registered Investment Advisors’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History

Edmonds Duncan Registered Investment Advisors’s Portfolio BIOR Stock Details BIOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-40
Closed -$12K – 144
2022
Q1 		$12K Hold
40
– – ﹤0.01% 142
2021
Q4 		$14K Buy
+40
New +$28.7K ﹤0.01% 145

Other funds holding BIOR

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Edmonds Duncan Registered Investment Advisors's BIOR Position: Q2 2022 in Review

Edmonds Duncan Registered Investment Advisors sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q2 2022, closing a stake of 40 shares — an estimated $12K sold.

Edmonds Duncan Registered Investment Advisors first reported a position in BIOR in Q4 2021 and held it in 2 quarters. The position peaked at $14K in Q4 2021. 46 funds tracked by Wall St. Rank hold BIOR as of Q2 2022.

  • Edmonds Duncan Registered Investment Advisors reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Edmonds Duncan Registered Investment Advisors sold 40 Biora Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $12K.
  • Edmonds Duncan Registered Investment Advisors first reported a position in Biora Therapeutics, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • Edmonds Duncan Registered Investment Advisors's Biora Therapeutics, Inc. Common Stock position peaked at $14K in Q4 2021.
  • 46 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Edmonds Duncan Registered Investment Advisors's 13F filing for Q2 2022, filed 20 Jul 2022.